INTRODUCTION

Tildrakizumab (brand name Ilumya) is a humanized IgG1-kappa monoclonal antibody that binds to IL-23A (IL-23p19) to inhibit interleukin-23 (IL-23). Tildrakizumab is used for the treatment of chronic plaque psoriasis.

RGBiotech offers Tildrakizumab expression plasmid vector. This plasmid vector is designed for expressing Tildrakizumab in mammalian expression system such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-185
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Tildrakizumab
Brand Name(s): Ilumya
Classification: Monoclonal antibody (mAb)
Target: IL-23A, IL-23p19, interleukin 23, IL23, IL-23
Amino Acid Sequence: Identical to DB14004

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.

[2] Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017 Jul 15;390(10091):276-288.

Contact Us